Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
UnitedHealth Group Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Current Ratio since 2005
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to UnitedHealth Group Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
Solvency ratios demonstrate a generally increasing reliance on debt financing over the observed period, though with some fluctuations. While coverage ratios initially remain strong, a clear downward trend emerges, indicating potential future challenges in meeting interest obligations.
- Debt to Equity
- The debt to equity ratio exhibits an increasing trend overall, rising from 0.65 in March 2022 to 0.86 in March 2025. There are quarterly variations, but the ratio generally remains above 0.70 after June 2022. A slight stabilization is observed in the latter part of the period, with values hovering around 0.84 to 0.83 from June 2024 through December 2025.
- Debt to Capital
- Similar to the debt to equity ratio, debt to capital shows a gradual increase, moving from 0.39 in March 2022 to 0.46 in March 2025. The ratio remains relatively stable between 0.43 and 0.46 from September 2022 through September 2025, before decreasing slightly to 0.45 in December 2025. This suggests a consistent, though moderate, increase in the proportion of debt used to finance the company’s capital structure.
- Debt to Assets
- The debt to assets ratio also demonstrates an upward trajectory, increasing from 0.21 in March 2022 to 0.26 in March 2025. The ratio remains relatively consistent between 0.25 and 0.26 from March 2024 through December 2025, indicating a sustained increase in the proportion of assets financed by debt.
- Financial Leverage
- Financial leverage, measured as total assets to equity, generally increased from 3.04 in March 2022 to 3.29 in September 2025, before stabilizing at 3.29 in December 2025. This indicates a greater use of assets relative to equity, amplifying both potential gains and losses. The ratio peaked at 3.49 in March 2023, then decreased before rising again.
- Interest Coverage
- The interest coverage ratio exhibits a consistent and significant downward trend. Starting at 14.26 in March 2022, it declines to 4.67 in December 2025. While initially very strong, indicating a substantial ability to cover interest expenses, the decreasing trend suggests a weakening capacity to meet these obligations from operating income. The most substantial declines occur after March 2023, with the ratio falling below 8.00 in March 2024.
In summary, the observed trends suggest a growing reliance on debt financing coupled with a diminishing ability to comfortably cover interest expenses. Continued monitoring of these ratios is warranted to assess potential risks associated with the increasing debt burden.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||
| Long-term debt, less current maturities | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Shareholders’ equity attributable to UnitedHealth Group | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity attributable to UnitedHealth Group
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio for the analyzed period demonstrates a generally increasing trend, with fluctuations throughout the observed timeframe. Initially, the ratio exhibited an increase from 0.65 in March 2022 to 0.71 in June 2022, followed by a slight decrease to 0.65 in September 2022. A subsequent rise to 0.74 was noted by December 2022.
A more pronounced upward trend occurred through the first half of 2023, peaking at 0.87 in March 2023. The ratio then moderated, decreasing to 0.80 in June 2023, 0.75 in September 2023, and 0.70 in December 2023. This suggests a period of debt reduction or equity growth, or a combination of both.
- Recent Trends (2024-2025)
- From December 2023 through December 2025, the debt to equity ratio has remained relatively stable, fluctuating between 0.83 and 0.86. The ratio increased from 0.70 in December 2023 to 0.85 in March 2024, and has remained within a narrow range since. The most recent value, 0.83 in December 2025, indicates a slight decrease from the peak observed in March 2024, but remains elevated compared to earlier periods in the analysis.
Overall, the company’s reliance on debt relative to equity has increased over the analyzed period, particularly between March 2022 and March 2023. While the ratio has stabilized in recent quarters, it remains at a higher level than observed at the beginning of the period, suggesting a shift in the company’s capital structure.
- Key Observations
- The most significant increase in the debt to equity ratio occurred between December 2022 and March 2023, indicating a substantial increase in debt or a decrease in equity during that period. The subsequent decline in the ratio through the remainder of 2023 suggests corrective actions were taken to manage leverage.
- The consistency of the ratio between 0.83 and 0.86 from March 2024 through December 2025 suggests a deliberate effort to maintain a specific capital structure, or that offsetting changes in debt and equity are occurring.
Debt to Capital
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||
| Long-term debt, less current maturities | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Shareholders’ equity attributable to UnitedHealth Group | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a generally increasing trend, with some quarterly fluctuations. Initially, the ratio stood at 0.39 in March 2022 and experienced a gradual increase to 0.46 by March 2024. Subsequent quarters show a slight stabilization around this level, with the ratio concluding at 0.45 in December 2025.
- Overall Trend
- The overall trend indicates a growing reliance on debt financing relative to capital over the observed timeframe. The ratio increased from 0.39 to 0.46 over two years, suggesting a shift in the company’s capital structure. While the increase isn’t dramatic, it warrants attention as continued increases could signal heightened financial risk.
- Short-Term Fluctuations
- Despite the overall upward trend, quarterly variations are present. A peak of 0.46 was observed in March 2024, June 2024, March 2025, and June 2025. These peaks are interspersed with periods of relative stability or slight decline, such as the decrease from 0.43 in September 2023 to 0.41 in December 2023. These fluctuations may be attributable to specific financing activities or changes in equity valuation during those quarters.
- Recent Performance
- The most recent quarters (September 2025 and December 2025) show a slight decrease in the debt to capital ratio, moving from 0.46 to 0.45. This suggests a potential stabilization or a minor reduction in debt relative to capital. However, this decrease is minimal and does not negate the overall increasing trend observed throughout the period.
The observed trend in the debt to capital ratio suggests that the company has been increasingly leveraging debt to finance its operations and growth. While not necessarily indicative of financial distress, continued monitoring of this ratio is recommended to assess the sustainability of the capital structure and potential implications for financial flexibility.
Debt to Assets
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings and current maturities of long-term debt | |||||||||||||||||||||
| Long-term debt, less current maturities | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio for the analyzed period demonstrates a generally increasing trend, indicating a growing reliance on debt financing relative to the company’s asset base. Initial values were relatively stable, followed by a more pronounced increase in later periods.
- Overall Trend
- The debt-to-assets ratio began at 0.21 in March 2022 and generally increased to 0.25 by September 2025. This represents a 19% increase over the observed period. The most significant increases occurred between December 2022 and March 2023, and again between March 2024 and September 2024.
- Short-Term Fluctuations (2022-2023)
- From March 2022 to June 2022, the ratio increased from 0.21 to 0.22. A slight decrease was then observed in September 2022 (0.20), before rising to 0.23 in December 2022. The most substantial increase within this timeframe occurred between December 2022 and March 2023, with the ratio climbing to 0.25. The ratio then decreased slightly to 0.23 in June 2023, remaining relatively stable through December 2023.
- Recent Stability (2024-2025)
- The ratio remained consistent at 0.26 from March 2024 through December 2024. A minor decrease to 0.25 was observed in both September 2025 and December 2025, suggesting a potential stabilization or slight de-leveraging at the end of the analyzed period. However, the ratio remained elevated compared to earlier periods.
- Debt and Asset Movements
- Total debt increased significantly from US$47,493 million in March 2022 to US$78,389 million in December 2025, representing a 65% increase. Total assets also increased, from US$221,238 million to US$309,581 million, a 40% increase. The faster growth of debt compared to assets is the primary driver of the increasing debt-to-assets ratio.
The observed trend suggests a shift in the company’s capital structure towards greater debt financing. Continued monitoring of this ratio is recommended to assess potential risks associated with increased leverage.
Financial Leverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Shareholders’ equity attributable to UnitedHealth Group | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity attributable to UnitedHealth Group
= ÷ =
2 Click competitor name to see calculations.
Financial leverage, as indicated by the ratio of total assets to shareholders’ equity attributable to UnitedHealth Group, exhibits a generally increasing trend over the observed period, with some fluctuations. The ratio began at 3.04 in March 2022 and generally increased through December 2022, before experiencing a decrease in the first half of 2023. A subsequent increase occurred through December 2023, followed by relative stability and a slight increase into June 2025.
- Initial Increase (Mar 31, 2022 – Dec 31, 2022)
- From March 2022 to December 2022, the financial leverage ratio increased from 3.04 to 3.16, then to 3.26, and finally settled at 3.16. This suggests an initial increase in the proportion of assets financed by debt or other non-equity sources. The increase from September to December 2022 was minimal, indicating a potential stabilization during that period.
- Mid-Term Fluctuation (Mar 31, 2023 – Dec 31, 2023)
- The ratio decreased from 3.49 in March 2023 to 3.40 in June 2023, then to 3.34 in September 2023, before decreasing further to 3.08 by December 2023. This indicates a reduction in financial leverage during this period, potentially due to increased equity or decreased asset levels. The decrease is notable, suggesting a deliberate shift in the company’s capital structure or a change in asset composition.
- Subsequent Stability and Slight Increase (Mar 31, 2024 – Jun 30, 2025)
- From March 2024 through June 2025, the ratio experienced relative stability, fluctuating between 3.28 and 3.29. The ratio began at 3.28 in March 2024, increased to 3.20 in June 2024, then to 3.17 in September 2024, and 3.22 in December 2024. The ratio then increased to 3.26 in March 2025, 3.26 in June 2025. This suggests a period of consistent capital structure management. The slight increase in the most recent periods indicates a renewed, albeit modest, tendency towards increased financial leverage.
Overall, the observed trend suggests a dynamic approach to financial leverage. While there was an initial increase followed by a notable decrease, the ratio has largely stabilized in recent periods, with a slight upward trend in the latest reported quarters. The fluctuations warrant further investigation to understand the underlying drivers of these changes in capital structure.
Interest Coverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net earnings (loss) attributable to UnitedHealth Group common shareholders | |||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | |||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Interest coverage
= (EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025)
÷ (Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio demonstrates a clear declining trend over the observed period. Initially strong, the ratio exhibits a consistent decrease, signaling a weakening ability to meet interest obligations from earnings before interest and tax.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The interest coverage ratio began at 14.26 and fluctuated between 13.59 and 14.66. This indicates a robust capacity to cover interest expenses with operating income during this timeframe. While some quarterly variation existed, the ratio remained consistently above 13.5, suggesting a comfortable margin of safety.
- Transition Phase (Mar 31, 2023 – Dec 31, 2023)
- A noticeable downward trend commenced in the subsequent period. The ratio decreased from 12.25 to 9.97, indicating a reduction in the earnings available to cover interest payments. This decline suggests increasing financial risk, although the ratio remained above 9 throughout the year.
- Accelerated Decline (Mar 31, 2024 – Dec 31, 2025)
- The rate of decline accelerated significantly. The ratio fell from 7.53 to 4.67 over the final two years of the observation period. This substantial decrease indicates a considerably diminished ability to service debt obligations from current earnings. The ratio’s movement below 6 suggests a heightened level of financial vulnerability. The final reported value of 4.67 represents a significant reduction from the initial values and warrants further investigation.
The concurrent increase in interest expense, while not dramatic in earlier periods, appears to contribute to the declining coverage ratio, particularly in the later quarters. The combination of decreasing EBIT and rising interest expense has created a challenging environment for maintaining a strong interest coverage position.
- EBIT and Interest Expense Relationship
- While EBIT experienced fluctuations, the consistent rise in interest expense, especially from March 2023 onwards, appears to be a key driver of the declining interest coverage ratio. The increasing cost of borrowing, coupled with periods of lower earnings, has progressively eroded the company’s ability to comfortably cover its interest obligations.
The observed trend suggests a growing reliance on external financing or a need to improve operational efficiency to bolster earnings and restore a more favorable interest coverage position.